Research Article Details
| Article ID: | A19169 |
| PMID: | 30280553 |
| Source: | Eksp Klin Gastroenterol |
| Title: | [LIPID PROFILE AND LIVER DISEASES AMONG PATIENTS WITH MORBID OBESITY]. |
| Abstract: | Objectives: The aim of our study was to investigate associations between the lipid profile, liver condition and the level of BMI. Methods: Our sample consisted of 58 patients: 30 - with morbid obesity and BMI - 40-49 (1 group), 28 - with superobesity, BMI - 50-69 (2 group). Lipids and hepatic functional tests were measured just prior to surgery. Ultrasound examination was used to estimate liver condition. Liver biopsy specimens were obtained at the time of surgery, classified according to the nonalcoholic fatty liver disease and steatohepatitis activity score. Results: Lower level of cholesterol has been found in the first group with morbid obesity. Higher level of triglycerides and very low-density lipoprotein has been found in the second group with superobesity (р=0,000 ANOVA). High-density lipoprotein was normal but significantly associated with BMI. The level of low-density lipoprotein was higher in the second group, but the difference between ptoups was not significant. BMI was associated with higher scores of ultrasonographic parameters and severity of steatosis, the increased prevalence of steatohepatitis and it activity. We also realized the positive correlation between ultrasonographic parameters and histological features. Conclusion: BMI has significantly positive correlations with the level of triglycerides and very low-density lipoprotein, ultrasonographic parameters, histological features of steatosis and steatohepatitis. The level of total cholesterol did not reflect all changes of lipid profile. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |